1,653
Participants
Start Date
December 16, 2015
Primary Completion Date
November 27, 2018
Study Completion Date
November 27, 2018
Rivaroxaban (Xarelto, BAY59-7939)
10mg OD (once-daily)
Acetylsalicylic Acid (ASA)
75-100mg OD
Clopidogrel
75mg OD
Rivaroxaban (Xarelto, BAY59-7939)
In case of NOAF, 20/15 mg OD (once-daily)
Vitamin K antagonist (VKA)
In case of NOAF, Open-label VKA therapy to target international normalized ratio (INR) 2-3, according to guidelines
Vienna
Vienna
Vienna
Bern
Hasselt
Genk
Liège
Linz
Basel
Wels
Salzburg
Lucerne
Lugano
Graz
Zurich
Aarhus N
Tromsø
New York
Prague
Berlin
Roslyn
Berlin
Berlin
Philadelphia
Washington D.C.
Milan
Milan
Milan
Hamburg
Baltimore
Charlottesville
Bad Segeberg
Kiel
Bergamo
Madrid
Bremen
Málaga
Brest
Atlanta
Hanover
Toulouse
Jacksonville
Oviedo
Miami
Clearwater
Padua
Fulda
Rotenburg A.d. Fulda
Chambray-lès-Tours
Magdeburg
Düsseldorf
Neuss
Dortmund
Cleveland
Cincinnati
Krefeld
Detroit
Angers
West Des Moines
Cologne
Aachen
Bonn
Mainz
Minneapolis
Pisa
Lille
Evanston
Frankfurt am Main
Chicago
Bad Nauheim
Kansas City
Homburg
Tübingen
Paris
Paris
Plano
Temple
Houston
Lahr
Konstanz
Freiburg im Breisgau
München
München
München
Ulm
Erlangen
Regensburg
Catania
Bad Neustadt an der Saale
Tacoma
Bad Berka
Los Angeles
Boston
Morristown
Manhasset
Winston-Salem
Wilkes-Barre
Houston
Burlington
Falls Church
Edmonton
Vancouver
Victoria
Winnipeg
Halifax
Newmarket
Toronto
Toronto
Montreal
Brno
Prague
Copenhagen
Odense C
Leipzig
Amsterdam
Breda
Rotterdam
Bergen
Oslo
Bielsko-Biala
Warsaw
Warsaw
Seoul
Seoul
Seoul
Seoul
L'Hospitalet de Llobregat
Barcelona
Uppsala
Brighton
Southampton
Blackpool
Leicester
Belfast
Newcastle upon Tyne
Leeds
Edinburgh
London
London
Oxford
Lead Sponsor
Janssen Research & Development, LLC
INDUSTRY
Bayer
INDUSTRY